ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Strattera (atomoxetine) by Year
Strattera (atomoxetine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly Strattera (atomoxetine): $451M in FY2019, down 27.1% from a year earlier. No newer figure appears in the documents we track.
Where the FY2019 figure comes from
“|| Strattera | 89.7 | 361.1 | 450.8 | 618.2 | (27 | )”
Source: Form 10-K FY2019 (filed 2020-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Strattera (atomoxetine) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 451 | -27.1% | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 618 | 0.0% | Form 10-K FY2018 (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 618 | -27.7% | Form 10-K (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | 855 | – | Form 10-K (filed 2018-02-20) ↗ |
Breakdown
What makes up strattera (atomoxetine)
Cite this data
StockData. (2026). Eli Lilly Strattera (atomoxetine) ($M), annual FY2016–FY2019 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-strattera-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.